FindTrial
Sign In

LEAP regimen

DRUG2 trials

Sponsors

Rong Tao

Conditions

Extranodal NK/T-cell LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Phase 2

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma
NCT04004572
Rong TaoNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Start: 2019-07-01End: 2022-12-30Target: 37Updated: 2021-01-28

Phase 3

BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
Not yet recruitingNCT07678229
Rong TaoExtranodal NK/T-cell Lymphoma
Start: 2026-07-01End: 2031-12-31Target: 150Updated: 2026-07-01

Related Papers

Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study.
2026-03-03
Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).
2021-10-2781 citations